Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Suspended 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 39Myelodysplastic Syndromes 15Leukemia, Myelomonocytic, Chronic 11Leukemia 4Myeloproliferative Disorders 3Anemia, Refractory, with Excess of Blasts 3Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Thrombocytosis 1Thrombocythemia, Essential 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Vorinostat 1Lenalidomide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × GATA2 Deficiency × Azacitidine × Clear all
NCT01522976 2026-04-30

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡